A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 47,000 shares of RYTM stock, worth $2.82 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
47,000
Previous 43,500 8.05%
Holding current value
$2.82 Million
Previous $1.79 Million 37.85%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$40.81 - $55.0 $4.19 Million - $5.65 Million
102,778 New
102,778 $5.38 Million
Q1 2024

May 15, 2024

SELL
$39.12 - $52.44 $4.3 Million - $5.76 Million
-109,817 Reduced 96.4%
4,098 $177,000
Q4 2023

Feb 14, 2024

SELL
$21.39 - $49.64 $3.03 Million - $7.02 Million
-141,518 Reduced 55.4%
113,915 $5.24 Million
Q3 2023

Nov 14, 2023

BUY
$15.81 - $27.8 $1.04 Million - $1.83 Million
65,901 Added 34.77%
255,433 $5.85 Million
Q2 2023

Aug 14, 2023

SELL
$16.32 - $21.15 $2.86 Million - $3.71 Million
-175,508 Reduced 48.08%
189,532 $3.13 Million
Q1 2023

May 15, 2023

BUY
$16.88 - $34.24 $4.97 Million - $10.1 Million
294,342 Added 416.34%
365,040 $6.51 Million
Q4 2022

Feb 14, 2023

BUY
$22.21 - $30.25 $330,107 - $449,605
14,863 Added 26.62%
70,698 $2.06 Million
Q3 2022

Nov 14, 2022

SELL
$4.3 - $30.85 $482,558 - $3.46 Million
-112,223 Reduced 66.78%
55,835 $1.37 Million
Q2 2022

Aug 15, 2022

SELL
$3.12 - $12.25 $255,421 - $1 Million
-81,866 Reduced 32.76%
168,058 $698,000
Q1 2022

May 16, 2022

BUY
$6.13 - $12.24 $1.33 Million - $2.66 Million
217,350 Added 667.25%
249,924 $2.88 Million
Q2 2021

Aug 16, 2021

SELL
$18.52 - $22.55 $1.6 Million - $1.94 Million
-86,134 Reduced 72.56%
32,574 $637,000
Q1 2021

May 17, 2021

BUY
$20.25 - $39.49 $823,405 - $1.61 Million
40,662 Added 52.1%
118,708 $2.53 Million
Q4 2020

Feb 16, 2021

BUY
$21.17 - $32.61 $1.05 Million - $1.62 Million
49,648 Added 174.83%
78,046 $2.32 Million
Q3 2020

Nov 16, 2020

BUY
$18.13 - $30.61 $514,855 - $869,262
28,398 New
28,398 $615,000
Q2 2020

Aug 14, 2020

SELL
$14.41 - $25.35 $299,122 - $526,215
-20,758 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$13.16 - $22.9 $82,078 - $142,827
6,237 Added 42.95%
20,758 $316,000
Q4 2018

Feb 14, 2019

BUY
$24.11 - $31.34 $16,177 - $21,029
671 Added 4.84%
14,521 $390,000
Q3 2018

Nov 13, 2018

SELL
$26.99 - $35.85 $981,491 - $1.3 Million
-36,365 Reduced 72.42%
13,850 $0
Q2 2018

Aug 10, 2018

SELL
$17.02 - $35.2 $69,509 - $143,756
-4,084 Reduced 7.52%
50,215 $0
Q1 2018

May 11, 2018

SELL
$19.9 - $32.25 $2.94 Million - $4.76 Million
-147,529 Reduced 73.1%
54,299 $1.08 Million
Q4 2017

Feb 09, 2018

BUY
$22.0 - $30.51 $4.44 Million - $6.16 Million
201,828
201,828 $5.87 Million

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $3.34B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.